ReviewAdvances in therapy2026
Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, characterized by the age-related decline in muscle mass and strength, increases the risk of falls, fractures, disability, and mortality. Type 2 diabetes and obesity frequently coexist with sarcopenia, contributing to the growing clinical challenge of sarcopenic obesity. Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, induce substantial weight loss through reduced calorie intake and are increasingly prescribed to older adults. However, weight reduction driven by appetite suppression may also decrease absolute protein intake, potentially compromising muscle health in individuals already vulnerable to anabolic resistance. This review examines the available evidence on changes in dietary protein intake during incretin-based therapy and their implications for muscle mass and functional preservation in older adults. Randomized trials suggest that liraglutide generally maintains protein intake as a proportion of total energy (approximately 13.9-17.5%), yet reductions in absolute protein intake may occur due to overall caloric restriction, particularly with more potent appetite suppression. Importantly, even when proportional intake is preserved, reductions in total energy intake may lower absolute protein consumption below levels required to adequately stimulate muscle protein synthesis in older adults. Comprehensive data on dietary intake remain limited, and few studies have systematically evaluated whether such changes translate into clinically meaningful declines in muscle mass, strength, or physical performance. Longer-term trials incorporating detailed dietary assessment, body composition analysis, and functional outcomes are needed to clarify the impact of incretin-based therapies on protein adequacy and muscle health in older adults. A clearer understanding of these interactions is essential to optimize weight management strategies while minimizing the risk of secondary sarcopenia.
Indexed as
Identifiers
42631799What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.